Trial · NCT01832259

A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

NCT01832259, Phase 2, Completed, University of Utah; results first posted 2018-06-12

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection. Trials, record NCT01832259. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01832259

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
NCT number: NCT01832259
Status: Completed
Phases: Phase 2
Enrollment: 30 participants, actual
Lead sponsor: University of Utah
Conditions: Adenocarcinoma of the Prostate
Interventions: Pazopanib, Placebo
First posted: 2013-04-16
Last updated: 2018-12-12
Results first posted: 2018-06-12

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)-Positive Clusters	1 month	Patients with high-risk, localized prostate cancer were treated with 28 days of Pazopanib or placebo, after which they underwent radical prostatectomy. During prostatectomy, benign pelvic lymph node tissue was collected and subsequently analyzed for the average number of VEGFR1-positive clusters in 8 distinct 40x microscopic fields as an indicator of pre-metastatic niche formation.
Secondary	Participants Experiencing Adverse Events	From first dose of study treatment to one month post-prostatectomy (approximately 2 months)	Adverse events were assessed using the Common Terminology for Adverse Events (CTCAE) version 4. Each event was assigned a grade (1-5), with lower grades indicating milder events. All adverse events were recorded, regardless of attribution to study treatment. For a full listing of Adverse Events, please see the Adverse Events section of the Results for this study.
Secondary	Biochemical Recurrence Progression Free Survival Rate	2 years	Following prostatectomy, patients' Prostate Specific Antigen (PSA) lab values were collected for up to two years. Biochemical recurrence was defined as the first PSA lab value of greater than or equal to 0.2 ng/mL following prostatectomy. Biochemical recurrence progression free survival rate was defined as the percent chance of 1 year survival with no biochemical recurrence.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)-Positive Clusters	1 month	The tissue of one patient on the Pazopanib arm and two patients on the Placebo arm was not able to be analyzed. Another patient on the Pazopanib arm had surgery delayed by a few weeks following stopping study medication and was determined to be unevaluable, resulting in 13 patients analyzed on each arm.	VEGFR1+ clusters per hpf	MEAN
SECONDARY	Participants Experiencing Adverse Events	From first dose of study treatment to one month post-prostatectomy (approximately 2 months)		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Biochemical Recurrence Progression Free Survival Rate	2 years	Two patients on the Pazopanib arm were not evaluable, one due to prostatectomy not being completed, and one due to prostatectomy being delayed outside of protocol windows.	percent chance of survival	NUMBER

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)-Positive Clusters	Placebo Arm		0.251560	Standard Deviation 0.093458902	VEGFR1+ clusters per hpf
Number of Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)-Positive Clusters	Pazopanib Arm		0.269518	Standard Deviation 0.120773334	VEGFR1+ clusters per hpf
Participants Experiencing Adverse Events	Placebo Arm	Participants experiencing Grade 1-2 Adverse Events	15		Participants
Participants Experiencing Adverse Events	Pazopanib Arm	Participants experiencing Grade 1-2 Adverse Events	15		Participants
Participants Experiencing Adverse Events	Placebo Arm	Participants experiencing Grade 3-4 Adverse Events	0		Participants
Participants Experiencing Adverse Events	Pazopanib Arm	Participants experiencing Grade 3-4 Adverse Events	4		Participants
Biochemical Recurrence Progression Free Survival Rate	Placebo Arm		73.3	95% Confidence Interval 54.0 to 99.5	percent chance of survival
Biochemical Recurrence Progression Free Survival Rate	Pazopanib Arm		92.3	95% Confidence Interval 78.9 to 100	percent chance of survival

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo Arm	15
Overall Study	STARTED	Pazopanib Arm	15
Overall Study	COMPLETED	Placebo Arm	15
Overall Study	COMPLETED	Pazopanib Arm	15
Overall Study	NOT COMPLETED	Placebo Arm	0
Overall Study	NOT COMPLETED	Pazopanib Arm	0

Source ClinicalTrials.gov

Adverse events168

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Abdominal pain	Gastrointestinal disorders	Placebo Arm	4	15
other	Abdominal pain	Gastrointestinal disorders	Pazopanib Arm	2	15
other	Agitation	Psychiatric disorders	Placebo Arm	1	15
other	Agitation	Psychiatric disorders	Pazopanib Arm	0	15
other	Alanine aminotransferase increased	Investigations	Placebo Arm	0	15
other	Alanine aminotransferase increased	Investigations	Pazopanib Arm	4	15	5
other	Alopecia	Skin and subcutaneous tissue disorders	Placebo Arm	0	15
other	Alopecia	Skin and subcutaneous tissue disorders	Pazopanib Arm	1	15
other	Anemia	Blood and lymphatic system disorders	Placebo Arm	2	15
other	Anemia	Blood and lymphatic system disorders	Pazopanib Arm	0	15

1 to 10 of 168Source ClinicalTrials.gov

See all 168 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo Arm	0	15
Total, all-cause mortality	Pazopanib Arm	0	15
Total, other adverse events	Placebo Arm	15	15
Total, other adverse events	Pazopanib Arm	15	15
Total, serious adverse events	Placebo Arm	0	15
Total, serious adverse events	Pazopanib Arm	0	15

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
30575560	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Pazopanib Arm vs Placebo Arm: deaths from any cause	Trial comparisons
Pazopanib Arm vs Placebo Arm: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01832259

GET https://conductscience.org/api/trials/v1/NCT01832259/events?page=2

API reference For AI assistants